A G Duffy1, S V Ulahannan1, L Cao2, O E Rahma1, O V Makarova-Rusher1, D E Kleiner3, S Fioravanti1, M Walker1, S Carey1, Y Yu2, A M Venkatesan4, B Turkbey5, P Choyke5, J Trepel6, K C Bollen7, S M Steinberg8, W D Figg7, T F Greten1. 1. Gastrointestinal Malignancies Section, Thoracic-GI Oncology Branch, Center for Cancer Research, National Cancer Institute, USA. 2. Genetics Branch, Center for Cancer Research, National Institutes of Health, USA. 3. Laboratory of Pathology, Center for Cancer Research, National Institutes of Health, USA. 4. Radiology and Imaging Sciences, Center for Cancer Research, National Institutes of Health, USA. 5. Molecular Imaging Department, Center for Cancer Research, National Institutes of Health, USA. 6. Developmental Therapeutics Branch, Center for Cancer Research, National Institutes of Health, USA. 7. Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA. 8. Biostatistics and Data Management, Center for Cancer Research, National Institutes of Health, USA.
Abstract
BACKGROUND: Endoglin is an endothelial cell membrane receptor essential for angiogenesis and highly expressed on the vasculature of many tumor types, including hepatocellular carcinoma (HCC). TRC105 is a chimeric IgG1 anti-CD105 monoclonal antibody that inhibits angiogenesis and tumor growth by endothelial cell growth inhibition, ADCC and apoptosis, and complements VEGF inhibitors. OBJECTIVE: The aim of this phase II study was to evaluate the efficacy of anti-endoglin therapy with TRC105 in patients with advanced HCC, post-sorafenib. METHODS: Patients with HCC and compensated liver function (Childs-Pugh A/B7), ECOG 0/1, were enrolled to a single-arm, phase II study of TRC105 15 mg/kg IV every two weeks. Patients must have progressed on or been intolerant of prior sorafenib. A Simon optimal two-stage design was employed with a 50% four-month PFS target for progression to the second stage. Correlative biomarkers evaluated included DCE-MRI as well as plasma levels of angiogenic biomarkers and soluble CD105. RESULTS: A total accrual of 27 patients was planned. However, because of lack of efficacy and in accordance with the Simon two-stage design, 11 patients were enrolled. There were no grade 3/4 treatment-related toxicities. Most frequent toxicities were headache (G2; N = 3) and epistaxis (G1; N = 4). One patient had a confirmed partial response by standard RECIST criteria and biologic response on DCE-MRI but the four-month PFS was insufficient to proceed to the second stage of the study. CONCLUSIONS: TRC105 was well tolerated in this HCC population following sorafenib. Although there was evidence of clinical activity, this did not meet prespecified criteria to proceed to the second stage. TRC105 development in HCC continues as combination therapy with sorafenib.
BACKGROUND:Endoglin is an endothelial cell membrane receptor essential for angiogenesis and highly expressed on the vasculature of many tumor types, including hepatocellular carcinoma (HCC). TRC105 is a chimeric IgG1 anti-CD105 monoclonal antibody that inhibits angiogenesis and tumor growth by endothelial cell growth inhibition, ADCC and apoptosis, and complements VEGF inhibitors. OBJECTIVE: The aim of this phase II study was to evaluate the efficacy of anti-endoglin therapy with TRC105 in patients with advanced HCC, post-sorafenib. METHODS:Patients with HCC and compensated liver function (Childs-Pugh A/B7), ECOG 0/1, were enrolled to a single-arm, phase II study of TRC105 15 mg/kg IV every two weeks. Patients must have progressed on or been intolerant of prior sorafenib. A Simon optimal two-stage design was employed with a 50% four-month PFS target for progression to the second stage. Correlative biomarkers evaluated included DCE-MRI as well as plasma levels of angiogenic biomarkers and soluble CD105. RESULTS: A total accrual of 27 patients was planned. However, because of lack of efficacy and in accordance with the Simon two-stage design, 11 patients were enrolled. There were no grade 3/4 treatment-related toxicities. Most frequent toxicities were headache (G2; N = 3) and epistaxis (G1; N = 4). One patient had a confirmed partial response by standard RECIST criteria and biologic response on DCE-MRI but the four-month PFS was insufficient to proceed to the second stage of the study. CONCLUSIONS: TRC105 was well tolerated in this HCC population following sorafenib. Although there was evidence of clinical activity, this did not meet prespecified criteria to proceed to the second stage. TRC105 development in HCC continues as combination therapy with sorafenib.
Authors: Michael S Gordon; Francisco Robert; Daniela Matei; David S Mendelson; Jonathan W Goldman; E Gabriela Chiorean; Robert M Strother; Ben K Seon; William D Figg; Cody J Peer; Delia Alvarez; Bonne J Adams; Charles P Theuer; Lee S Rosen Journal: Clin Cancer Res Date: 2014-09-26 Impact factor: 12.531
Authors: Dieter Koeberle; Michael Montemurro; Panagiotis Samaras; Pietro Majno; Mathew Simcock; Andreas Limacher; Stefanie Lerch; Katalin Kovàcs; Roman Inauen; Vivianne Hess; Piercarlo Saletti; Markus Borner; Arnaud Roth; György Bodoky Journal: Oncologist Date: 2010-03-04
Authors: D Y Li; L K Sorensen; B S Brooke; L D Urness; E C Davis; D G Taylor; B B Boak; D P Wendel Journal: Science Date: 1999-05-28 Impact factor: 47.728
Authors: Andrew B Nixon; Herbert Pang; Mark D Starr; Paula N Friedman; Monica M Bertagnolli; Hedy L Kindler; Richard M Goldberg; Alan P Venook; Herbert I Hurwitz Journal: Clin Cancer Res Date: 2013-10-04 Impact factor: 12.531
Authors: Nikolaos A Dallas; Shaija Samuel; Ling Xia; Fan Fan; Michael J Gray; Sherry J Lim; Lee M Ellis Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: Annamaria Rapisarda; Melinda Hollingshead; Badarch Uranchimeg; Carrie A Bonomi; Suzanne D Borgel; John P Carter; Bradley Gehrs; Mark Raffeld; Robert J Kinders; Ralph Parchment; Miriam R Anver; Robert H Shoemaker; Giovanni Melillo Journal: Mol Cancer Ther Date: 2009-07-07 Impact factor: 6.261
Authors: Yingmiao Liu; Hongyu Tian; Gerard C Blobe; Charles P Theuer; Herbert I Hurwitz; Andrew B Nixon Journal: Invest New Drugs Date: 2014-07-05 Impact factor: 3.850
Authors: Emily B Ehlerding; Carolina A Ferreira; Eduardo Aluicio-Sarduy; Dawei Jiang; Hye Jin Lee; Charles P Theuer; Jonathan W Engle; Weibo Cai Journal: Mol Pharm Date: 2018-05-30 Impact factor: 4.939
Authors: Austin G Duffy; Chi Ma; Susanna V Ulahannan; Osama E Rahma; Oxana Makarova-Rusher; Liang Cao; Yunkai Yu; David E Kleiner; Jane Trepel; Min-Jung Lee; Yusuke Tomita; Seth M Steinberg; Theo Heller; Baris Turkbey; Peter L Choyke; Cody J Peer; William D Figg; Brad J Wood; Tim F Greten Journal: Clin Cancer Res Date: 2017-05-02 Impact factor: 12.531
Authors: Keina M C Dourado; June Baik; Vanessa K P Oliveira; Miriam Beltrame; Ami Yamamoto; Charles P Theuer; Camila A V Figueiredo; Michael R Verneris; Rita C R Perlingeiro Journal: Blood Date: 2017-03-28 Impact factor: 22.113
Authors: Hong-Wei Wu; Michael A Sheard; Jemily Malvar; G Esteban Fernandez; Yves A DeClerck; Laurence Blavier; Hiroyuki Shimada; Charles P Theuer; Richard Sposto; Robert C Seeger Journal: Clin Cancer Res Date: 2019-05-08 Impact factor: 12.531